Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brensocatib (Primary)
  • Indications Bronchiectasis
  • Focus Therapeutic Use
  • Acronyms Willow
  • Sponsors Insmed

    • Most Recent Events

    • 13 Sep 2023 Results assessing baseline characteristics and treatment outcomes by eosinophilic endotype (eosinophil count ) among WILLOW patients presented at the 33rd Annual Congress of the European Respiratory Society
    • 13 Sep 2023 Results assessing whether Brensocatib 25mg significantly increases sputum SLPI levels indicating downstream effects of protease inhibition on host defence, presented at the 33rd Annual Congress of the European Respiratory Society
    • 24 May 2023 Results assessing whether brensocatib would reduce airway AZU1 levels in patients with bronchiectasis presented at the 119th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top